FDA’s New Criminal Investigations Chief Wants Global Reach
This article was originally published in The Tan Sheet
Executive Summary
Office of Criminal Investigations Director George Karavetsos talks about the Park Doctrine and off-label enforcement in an interview.
You may also be interested in...
US FDA’s OCI Director Is Leaving For Private Practice
George Karavetsos’ last day is Jan. 20, which coincidentally is the start of the Trump Administration. Office of Criminal Investigations has been subject of recent Congressional scrutiny.
FDA's Beleaguered Criminal Investigations Unit Now Facing Congressional Scrutiny
After staff complain about becoming the 'Botox police,' a House committee is asking FDA for an update on two previous reports raising issues of management and morale in the Office of Criminal Investigations.
FDA Reprint Policy Expands To Clinical Practice Guidelines, Medical Reference Texts
FDA has revised, but not loosened, its 2009 final guidance on good reprint practices for distribution of journal articles on unapproved uses of approved drugs and devices.